Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Holding HRMY?
Track your performance easily
HRMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.61 - $39.73
Previous Close$38.34
Volume174.66K
Average Volume (3M)387.39K
Market Cap
$2.18B
Enterprise Value$2.02B
Total Cash (Recent Filing)$346.91M
Total Debt (Recent Filing)$186.42M
Price to Earnings (P/E)19.6
Beta0.77
Next Earnings
Oct 29, 2024EPS Estimate
$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.95
Shares Outstanding56,834,745
10 Day Avg. Volume400,596
30 Day Avg. Volume387,387
Standard Deviation0.13
R-Squared0.08
Alpha0.00037
Financial Highlights & Ratios
Price to Book (P/B)4.04
Price to Sales (P/S)3.36
Price to Cash Flow (P/CF)12.90
P/FCF Ratio12.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit4.38
Enterprise Value/Ebitda12.22
Forecast
1Y Price Target
$47.33Price Target Upside21.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Harmony Biosciences Holdings News
PremiumCompany Announcements
Harmony Biosciences Executive Resigns, Subsidiary RenamedBulls Say, Bears Say
Bulls Say
Diversification And Long-term RevenuePipeline assets from recent business development deals could bring in attractive diversification opportunities.
Pipeline And Product LaunchesThe company is expected to drive growth through at least one new product or indication launch each year over the next 5 years.
Regulatory And Market PositionFDA approval for Wakix in pediatric patients with narcolepsy builds overall confidence in the asset duration for Wakix.
Bears Say
Market OpportunityThe market opportunity within pediatric patients is relatively small, accounting for ~5% of the overall patient population within narcolepsy.
Regulatory ApprovalHRMY received a complete response letter (i.e., did not receive approval) for Wakix to treat cataplexy in pediatric narcolepsy.
Stock PerformanceHRMY shares have underperformed year-to-date and on a one-year basis.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $18.61 and its highest was $39.73 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Currently, no data Available
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Oct 29, 2024 which is in 39 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Aug 06, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of -$0.002 by $0.202.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is $0.66.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 56,834,743 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.2 in its last earnings report, beating expectations of -$0.002. Following the earnings report the stock price went up 6.177%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Among the largest hedge funds holding Harmony Biosciences Holdings’s share is Royce & Associates LLC. It holds Harmony Biosciences Holdings’s shares valued at 3M.
---
Harmony Biosciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.33 (21.48% Upside)
$47.33 (21.48% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 30.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.64%
12-Months-Change
Fundamentals
Return on Equity
22.46%
Trailing 12-Months
Asset Growth
12.92%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
---
HRMY Company Deck
---
HRMY Earnings Call
Q2 2024
0:00 / 0:00
---
HRMY Stock 12 Month Forecast
Average Price Target
$47.33
▲(21.48% Upside)
Technical Analysis
Best Analysts Covering HRMY
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+13.33%
reiterated a buy rating last month
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +13.33% per trade.
---